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Abstract – In this study, speciﬁc sequences within three genes (3D, VP4 and 2B) of the foot-and-mouth
disease virus (FMDV) genome were determined to be effective RNAi targets. These sequences are highly
conserved among different serotype viruses based on sequence analysis. Small interfering RNA (siRNA)-
expressing plasmids (p3D-NT19, p3D-NT56, pVP4-NT19, pVP4-NT65 and p2B-NT25) were constructed
to express siRNA targeting 3D, VP4 and 2B, respectively. The antiviral potential of these siRNA for various
FMDV isolates was investigated in baby hamster kidney (BHK-21) cells and suckling mice. The results
show that these siRNA inhibited virus yield 10- to 300-fold for different FMDV isolates of serotype O and
serotype Asia I at 48 h post infection in BHK-21 cells compared to control cells. In suckling mice, p3D-
NT56 and p2B-NT25 delayed the death of mice. Twenty percent to 40% of the animals that received a
single siRNA dose survived 5 days post infection with serotype O or serotype Asia I. We used an attenuated
Salmonella choleraesuis (C500) vaccine strain, to carry the plasmid that expresses siRNA directed against
the polymerase gene 3D (p3D-NT56) of FMDV. We used guinea pigs to evaluate the inhibitory effects of
recombinant S. cho (p3D-NT56/S. cho) on FMDV infection. The results show that 80% of guinea pigs
inoculated with 10
9 CFU of p3D-NT56/S. cho and challenged 36 h later with 50 ID50 of homologous
FMDV were protected. We also measured the antiviral activity of p3D-NT56/S. cho in swine. The results
indicate that 100% of the animals treated with 5 · 10
9 CFU of p3D-NT56/S. cho were protected in 9 days.
foot-and-mouth disease virus / RNA interference / Salmonella choleraesuis / conserved sequence /
swine
1. INTRODUCTION
Short interfering RNA (siRNA) are small,
double-stranded RNA molecules that direct
the degradation of complementary messenger
RNA via a cellular process known as RNA
interference. It is widely believed that RNA
interference is an evolutionarily conserved
mechanism within eukaryotes and that its func-
tions include endogenous gene regulation, viral
defense and the maintenance of genomic stabil-
ity [14]. Because of the rapidity and speciﬁcity
of RNAi, this technology could complement
and improve the traditional tools available to
control important animal pathogens.
Foot-and-mouth disease (FMD) is an extre-
mely contagious disease that affects more than
33 species of cloven-hoofed animals including
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial License
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any
noncommercial medium, provided the original work is properly cited.
* Corresponding author: zxzheng@fudan.edu.cn
Vet. Res. (2010) 41:30
DOI: 10.1051/vetres/2010002
  INRA, EDP Sciences, 2010
www.vetres.org
Article published by EDP Sciencescattle, swine, and other livestock [36]. The dis-
ease has been known for ﬁve centuries and its
causative agent, the FMD virus (FMDV),
belongs to the genus Aphthovirus of the family
Picornaviridae [1]. The FMDV genome is
composed of a positive-sense, single-stranded
RNA molecule of about 8500 nucleotides that
contains a unique open reading frame. Like
other RNA viruses, FMDV is antigenically var-
iable and undergoes rapid mutation. There are
seven distinguishable serological types of
F M D V ,n a m e l yO ,A ,C ,A s i aI ,S A T 1 ,S A T 2 ,
and SAT3. Current FMD vaccines based on
inactivated virus are effective in preventing
the disease, but carry the risks of incomplete
inactivation and viral escape from vaccine pro-
duction laboratories [26] ,a n dt h e yf a i lt oi n d u c e
an immune response in a short period. Thus, the
development of emergency antiviral strategies
is necessary in order to stem outbreaks of FMD.
Asanantiviraltechnology,RNAihasalready
been widely researched for use with FMDV
[5, 24, 33]. However, establishing RNAi as a
viable approach to prevent FMDV requires
resolving at least one major issue [17, 20]: the
high genetic variability of FMD viruses. RNAi
directed toward speciﬁc gene sequences of cer-
tain FMDV strains may face risks, especially
in the event of an emergent FMD outbreak,
because no information about the serotype or
genotype of the isolated pathogen would be
available while early protection is needed.
Therefore, it may be necessary to design several
siRNA that focus on the conserved regions of
the viral genome [16, 17, 42, 46]. Previously,
we showed that siRNA generated in vitro can
effectively inhibit the replication of FMDV in
either a speciﬁc or cross-inhibitory manner
[28]. Another crucial issue that needs to be
addressed is the optimal vector for delivery of
siRNA-expressing cassettes. Chen et al. [6]
demonstrated that treatment with recombinant,
replication-defective human adenovirus type 5
expressing short-hairpin RNA signiﬁcantly
reduces the susceptibility of guinea pigs and
swine to FMDVinfection. However, adenovirus
VA1 non-coding RNA is able to inhibit the
biogenesis of siRNA and microRNA [30]. This
ﬁnding suggests that novel siRNA delivery
systems would be necessary.
Salmonella, a member of enteric bacilli, is
one of the most severe etiological agents of
food-borne diseases. It is widely accepted that
recombinant live vaccines using attenuated
Salmonella as a vector to deliver passenger anti-
gen induce immune responses not only against
salmonella infection, but also against passenger
pathogenic infection [8]. Live-attenuated
Salmonella has been shown to deliver DNA
vaccines [9, 35, 41, 47]. Early in the 1970s,
Fang et al. screened out an attenuated Salmo-
nella choleraesuis C500, which was a licensed
live vaccine against swine paratyphoid [13]. Liu
et al. proved that the attenuated S. choleraesuis
C500 carrying an oral DNAvaccine induced an
immune response against FMDV [29].
In the present study, we constructed several
siRNA-expressing plasmids targeted to con-
served sequences within the coding regions of
viral polymerase protein 3D, capsid protein
VP4 and nonstructural (NP) protein 2B of the
FMDV genome. Some of the plasmids inhib-
ited several isolates of serotype O and serotype
Asia I FMDV in baby hamster kidney (BHK-
21) cells and suckling mice. Furthermore, we
reported that siRNA directed against the poly-
merase protein 3D of FMDV and delivered by
attenuated S. choleraesuis were capable of
inhibiting virus replication in guinea pigs and
swine.
2. MATERIALS AND METHODS
2.1. Bacteria and plasmids
The attenuated vaccine strain S. choleraesuis
C500 was obtained from Nanjing Biological Pharma-
ceutical Co., Ltd. Attenuated Salmonella typhimuri-
um LB5010 was kindly provided by Prof. Aoquan
Wang (Institute of Microbiology, Chinese Academy
of Sciences). The plasmid pU6, which has the mouse
U6 promoter (PU6), was constructed and maintained
in our laboratory.
2.2. Animals
Suckling mice (C57BL/6), 2 to 3 days old and
weighing 3 to 4 g, were maintained by Bio-phar-
macy, Jinyu Group Co., Ltd. Male and female guinea
pigs weighing 250 to 300 g and large white swine,
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used to perform viral challenge. All of the animals
were housed in disease-secure isolation facilities in
an FMDV-free area, and had no previous FMD con-
tact as conﬁrmed by the absence of detectable anti-
FMDV antibodies in their sera.
2.3. Cells and viruses
Human kidney cells (AD-293) were used to grow
recombinant replication-defective human adenovi-
ruses (rAd5) and determine virus titers. BHK-21 cells
wereusedtogrowFMDVanddeterminevirusinfectiv-
ity. Both of the cell lines were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (pH
7.4). Cultures were incubated at 37  Cw i t h5 %C O 2.
Two FMDV isolates of serotype O (HKN/2002
(GenBank accession number AY317098) and CHA/
99 (GenBank accession number AJ539138)) and
two FMDV isolates of serotype Asia I (YNBS/58
(GenBankaccessionnumberAY390432)andJiangsu/
2005 (GenBank accession number EF149009)) were
used for viral challenge.
Recombinant replication-defective human adeno-
viruses (Ad5-POL and Ad5-LacZ) were constructed
a n dm a i n t a i n e di no u rl a b o r a t o r y[ 6]. Ad5-POL
expressed siRNA targeting the FMDV 3D sequence
corresponding to nucleotides (nt) 1225–1280 of
HNK/2002 3D. As a control for nonspeciﬁc effects
of rAd5, Ad5-LacZ expressed siRNA corresponding
to nt 1353 to 1435 of the b-galactosidase gene of
Escherichia coli, which has no homology to the
HKN/2002 genome as conﬁrmed by sequence analy-
sis. The sequence of Ad5-POL encoding the FMDV
3D-speciﬁc siRNA was 50-GAGGCTATCCTCTC
CTTTGCACGCCGTGGGACCATACAGGAGAAG
TTGATCTCCGT-30 (sense), and that of Ad5-LacZ
encoding the E. coli b-galactosidase-speciﬁc siRNA
was 50-GAGTGTGATCATCTGGTCGCTGGGGA
ATGAATCAGGCCACGGCGCTAATCACGACGC
GCTGTATCGCTGGATCAAATCTGTCG-30 (sense).
2.4. Construction of siRNA-expressing plasmids
As a general strategy for constructing siRNA-
expressing plasmids, inverted repeats targeting the
sequence were cloned into plasmid pU6 at the
EcoRI/HindIII sites, under the control of the U6 pro-
moter and the termination signals of 4 or 5 thymi-
dines. Plasmids p3D-NT19, p3D-NT56, pVP4-
NT19, pVP4-NT65 and p2B-NT25 contained
inverted repeats corresponding to the nucleotide
sequences of the FMDV genome, as described below.
As negative controls for nonspeciﬁc effects, plasmid
pNTH21 and pLacZ contained inverted repeats of
21 nt and 83 nt, respectively, which have no homol-
ogy to the FMDV genome, as conﬁrmed by sequence
analysis.
The targets of interest were essential during the
life cycle of FMDV and relatively conserved in their
nucleotide sequences. The reference sequences of the
conserved regions of the FMDV genome were
obtained from the National Center for Biotechnology
Information (NCBI) website
1 and compared
by nucleotide (nt) BLAST. The sequence of
3D-NT19 was 50-GTTCTTGGTCACTCCATAA-30,
corresponding to nt 1123–1141 of the HKN/2002
3D gene; the sequence of 3D-NT56 was 50-GAG
GCTATCCTCTCCTTTGCACGCCGTGGGACCAT
ACAGGAGAAGTTGATCTCCGT-30, correspond-
ing to nt 1225–1280 of the HKN/2002 3D gene;
the sequence of VP4-NT65 was 50-TCAGGCAA
CACTGGAAGCATCATTAACAACTACTACATGC
AGCAGTACCAGAACTCCATGGACAC-30, corre-
sponding to nt 43–107 of the YNBS/58 VP4 gene;
the sequence of VP4-NT19 was 50-ACAACTACTA
CATGCAGCA-30, corresponding to nt 68–86 of the
YNBS/58 VP4 gene; the sequence of 2B-NT25
was 50-CCAGATGCAGGAGGACATGTCAACA-30,
corresponding to nt 57–81 of the CHA/99 2B gene.
2.5. Cell transfection and viral challenge assays
Virus infectivity was determined by serial dilution
of the sample on BHK-21 cells grown in 96-well
plates and the virus titer was calculated as a tissue
culture infective dose by the Reed–Muench method
[38]. A viral suspension titrated at 10
5 to 10
7 TCID50
per 0.1 mL was used for viral challenge. BHK-21
cells were seeded in 96-well plates in DMEM 24 h
before transfection. The cells (about 95% conﬂuent)
were transiently transfected with 0.1 lgo fas i n g l e
plasmid expressing 3D, VP4 or 2B speciﬁc siRNA.
Five hours after transfection, the transfection com-
plex was removed, cells were washed twice with
DMEM, and 100 TCID50 of FMDV per 0.1 mL
was added to each well. After 1 h of adsorption,
the inoculum was removed and cells were washed
twice with DMEM. The infection then proceeded in
DMEM supplemented with 10% fetal bovine serum.
Cell supernatants were collected at designated time
points, and the virus titers were determined three
times on BHK-21 cells. Statistical analysis was per-
formed with the Microsoft Excel program (Microsoft,
Redmond, WA, USA).
1 www.ncbi.nlm.nih.gov
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Suckling mice (8 groups of 20 each) were subcu-
taneously injected in the neck with 100 lg of plas-
mids in 100 lL of phosphate-buffered saline (PBS).
A f t e r6h ,t h es u c k l i n gm i c ew e r ec h a l l e n g e dw i t h
20 LD50 of FMDV per 0.1 mL via subcutaneous
injection into the neck near the site that received
the injected DNA. The mice were then observed
for 5 days post-challenge (dpc). Statistical analysis
was performed with a log rank test
2.
2.7. Construction and identiﬁcation
of recombinant attenuated S. choleraesuis
In order to prepare the recombinants (p3D-NT19/
S. cho, pLacZ/S. cho and p3D-NT56/S. cho), the
attenuated S. typhimurium LB5010, an intermediate
host cell, was ﬁrst transformed with plasmids (pLacZ,
p3D-NT56 and p3D-NT19) using a standard CaCl2
method. Then, the plasmids were extracted and trans-
ferred to a terminal host cell-attenuated S. cholerae-
suis C500 by electroporation. The preparation of
cells for electroporation was as follows: C500 cells
were cultured in 3 mL LB medium at 200 rpm over-
n i g h ta t3 7 C ,a n dt h e nw e r ei n o c u l a t e di n t o2 5m L
liquid LB medium at 1% (v/v) at 37  C, again with
s h a k i n ga t2 0 0r p m .B a c t e r i aw e r eg r o w nt oa no p t i -
cal density (OD) of 0.6–0.7, chilled and then col-
lected by centrifugation at 4 000 rpm for 10 min at
4  C. The cells were then washed with 10% glycerol
three times. The cells were re-suspended in 10%
glycerol at a concentration of 3 · 10
10 cells/mL, fro-
z e ni nd r yi c e ,a n ds t o r e da t 70  C. A 200 lL ali-
quot of the cells was thawed and used for
transformation. One microgram DNA (the control
setup with no DNA) was mixed with cold cell sus-
pension and then transferred to a chilled cuvette.
Transformation was carried out with a Bio-Rad Gene
Pulser at 2.0 kV, 25 lF, 200 X at 0–4  C. Trans-
formed competent cells were transferred to a tube,
and 400 lL of media were added prior to incubating
the cultures for 1.5 h at 50 rpm at 37  C. Then,
80 lL of the cultures were transferred onto solid
LB medium containing 100 lL/mL ampicillin.
Recombinant bacteria were identiﬁed via PCR. The
presence of the recombinant plasmid was conﬁrmed
by digestion with XhoI. Serological characteristics
of recombinant S. choleraesuis (rS. cho)w e r et e s t e d
using a congregation reaction on a glass plate to con-
ﬁrm its immunogenicity.
2.8. Viral challenge in guinea pigs and swine
Live bacteria were prepared by culturing cells in
25 mL liquid LB medium at 37  C for 18 h fol-
lowed by inoculation of 2.5 mL cultures into
25 mL liquid LB medium to produce 2 · 10
9–
5 · 10
9 CFU/mL. Live bacteria counting was per-
formed by serial dilution of cultures followed by
spread plating. Serotype O FMDV strain HKN/
2002 passaged ﬁve times in suckling mice was used
to challenge guinea pigs, and the virus passaged
three times in swine was used for swine experi-
ments. The viruses were titrated on guinea pigs
and swine. The dose of FMDV used was determined
through four 10-fold serial dilutions of virus (i.e.
10
 4,1 0
 5,1 0
 6, and 10
 7) in PBS. Guinea pigs
(4 groups of 6 animals each) were inoculated intra-
dermally in the left rear foot with 0.1 mL of serially
diluted viruses. According to the method described
by Chen et al. [6], the swine (4 groups of 4 each)
were inoculated in the neck region by intramuscular
injection of each animal with 2 mL of serially
diluted virus. All of the animals were then monitored
for the major clinical sign of FMD, the appearance
of vesicles on the mouth or feet. The 50% animal
infective dose (ID50) was estimated using the
Reed–Muench method [38]. Statistical analysis was
performed with a log rank test
2.
2.8.1. Guinea pig experiment 1
Guinea pigs in several groups of ﬁve each
were inoculated by intramuscular injection with
1.0 · 10
9 CFU of recombinant attenuated
S. choleraesuis in 0.1 mL of saline. Thirty-six hours
after inoculation, FMDV challenge was carried out
via intradermal injection of each animal with
0.1 mL of guinea pig infectious dose 50 ID50 of
HKN/2002 in the left rear foot, as was done for
virus titration.
2.8.2. Guinea pig experiment 2
In a parallel experiment, animals were treated with
1.0 · 10
6 PFU of rAd5 and challenged 36 h later
with 50 ID50 of HKN/2002. To test whether the com-
bined inoculations of rAd5 and rS. cho protected
animals, some groups were injected intramuscu-
larly with the p3D-NT56/S. cho+Ad5-POL mixture
of 1.0 · 10
9 CFU and 1.0 · 10
6 PFU, respectively;
then, after 36 h, they were challenged with 50 ID50
of HKN/2002.
2 http://bioinf.wehi.edu.au/software/russell/logrank/
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Eighteen swine were divided into 5 groups of 3 or
4 animals each. The animals in each group were co-
housed in a separate room. All groups were inocu-
lated via intramuscular injection in the neck area.
Group 1 was a mock control group inoculated with
2 mL of saline. As negative controls, groups 2 and
3 were inoculated with 5 · 10
9 CFU of S. cholerae-
suis C500 or LacZ/S. cho in 2 mL of saline, respec-
tively. Group 4 was inoculated with 5 · 10
9 CFU of
p3D-NT56/S. cho in 2 mL of saline. Group 5 was
treated with a high dose of p3D-NT56/S. cho contain-
ing 5 · 10
10 CFU in 2 mL of saline. After 24 h, all
animals were challenged via intramuscular injection
with 100 ID50 of HKN/2002 in 2 mL of PBS in
the neck area. To avoid overexposure to the challenge
virus, animals that developed disease were moved to
another room, and then observation proceeded. After
challenge, the animals were examined daily for clin-
ical signs of FMD, including an increase in body
temperature (above 40  C) and the appearance of
vesicles on the mouth and feet. The lesion score
was determined at various time points post-challenge
by determining the number of digits plus mouth with
vesicles for each animal. The observations were ter-
minated on day 14 post-challenge, when the animals
were humanely killed.
2.9. Serological analysis
Blood and serum samples were collected at days
7 and 14 after challenge in swine experiments. To
assess the neutralizing antibody response in the
swine, plaque reduction neutralization assays were
performed as described previously [31]. Neutralizing
titers were reported as the highest serum dilution
causing a 50% reduction in the number of HKN/
2002 plaques on BHK-21 cells. The presence of anti-
bodies against viral NS protein 3ABC of FMDV in
the sera was detected using a solid-phase blocking
enzyme-linked immunosorbent assay (SPB-ELISA)
according to the procedures described by Chenard
et al. [7]. Brieﬂy, ELISA microtiter test plates were
coated overnight at 4  C with recombinant 3ABC
antigen expressed in E. coli [45]. After ﬁve washes
with PBS containing 0.05% Tween 80 (PBST), each
well of the plates was ﬁlled with 100 lLo ft e s to r
reference serum diluted 1:2 in PBST and incubated
at 37  C for 60 min. The serum was then removed,
and the wells of the plates were washed as described
above. After rewashing, 100 lL of anti-3ABC
immunoglobulin–horseradish peroxidase conjugate
was added, and the incubation proceeded at 37  C
for 30 min. The conjugate was then removed, the
wells of the plates were washed again, and 100 lL
of a commercially ready-to-use tetramethyl benzidine
chromogen substrate was added to the plates. After
incubation at 37  C for 10 min, the reaction was
s t o p p e db ya d d i n g5 0lLo f2 . 0MH 2SO4 per well,
and the OD at 450 nm was measured by using an
ELISA reader. The sera were considered positive if
the OD was reduced by   30% compared to a stan-
dard negative serum corrected for background signal
by subtracting the OD of the high positive reference
serum. Statistical analysis was performed with the
Microsoft Excel program.
3. RESULTS
3.1. FMDV-speciﬁc siRNA-expressing plasmids
induced antiviral effects to different isolates
of serotype O and serotype Asia I FMDV
in BHK-21 cells
To test the antiviral activity of siRNA,
BHK-21 cells cultured in 96-well plates were
transfected with siRNA-expressing plasmids
individually. As controls, the cells were either
not treated or treated with plasmid pNTH21 or
pLacZ. After 24 h, the cells were infected with
100 TCID50 of CHA/99, HNK/2002, YNBS/
58 or Jiangsu/2005. The cells were observed
continuously under the microscope. Micros-
copy examination revealed that the cells trea-
ted with p3D-NT56 or p2B-NT25 had
delayed cytopathic effect (CPE) development
when challenged with either serotype O or
Asia I of FMDV. However, the control cells,
either blank or transfected with the control
plasmids, showed an extensive CPE within
24 h post infection (p.i.).
Furthermore, we investigated the effect of
plasmid-mediated RNAi on FMDV replication
by measuring the TCID50 of supernatants of
lysed cells, which were collected at 12, 24
and 48 h after viral challenge. Consistent with
the observation, p3D-NT56 and p2B-NT25
showed a wider cross-inhibitory effect than
the other plasmids, and these 2 plasmids inhib-
ited 4 FMDV isolates (Fig. 1). The supernatant
TCID50 for CHA/99, HNK/2002, YNBS/58
and Jiangsu/2005 of the cells treated with
p3D-NT56 or p2B-NT25 was reduced by
Salmonella-mediated RNAi against FMDV Vet. Res. (2010) 41:30
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compared to the control groups.
3.2. Treatment with siRNA-expressing plasmids
conferred resistance against FMDV in
suckling mice
To further examine the anti-FMDV potential
of p3D-NT56 or p2B-NT25 in vivo, we chal-
lenged suckling mice pretreated by subcutane-
ous injection of plasmids with FMDV strains
HKN/2002 or YNBS/58. All PBS-treated mice
died within 60 h after either HNK/2002 or
YNBS/58 challenge (Fig. 2). The animals trea-
ted with control plasmids were also not pro-
tected at all, although death in some groups
was delayed slightly (p=0.47, p=0.157)
(Fig. 2). In HKN/2002 challenge experiments,
20% of the animals treated with either p3D-
NT56 or p2B-NT25 were protected (Fig. 2A).
The difference between the survival of mice
treated with either p3D-NT56 or p2B-NT25
and the PBS control was statistically signiﬁcant
(p < 0.0001). In the case of challenge with
YNBS/58, 8 of 20 mice treated with p3D-
NT56 and 7 of 20 mice treated with p2B-
NT25 survived a viral challenge of 20 LD50
(Fig. 2B), and a signiﬁcant difference in mouse
survival was seen between mice treated with
either p3D-NT56 or p2B-NT25 and controls
(p < 0.0001). Furthermore, in both HNK/2002
and YNBS/58 challenge assays, the time of
50% death of mice was delayed for 9 to 24 h
in groups treated with FMDV-speciﬁc siRNA-
expressing plasmids as compared with control
groups.
Figure 1. Decrease of virus yield in BHK-21 cells treated with siRNA-expressing plasmids. Cells
transiently transfected with either control plasmids or speciﬁc siRNA-expressing plasmids were infected
with 100 TCID50 of FMDV HKN/2002 (A), FMDV CHA/99 (B), FMDV YNBS/58 (C) and FMDV
Jiangsu/2005 (D) per 0.1 mL. Culture supernatants were collected at different times, and the virus titer
(TCID50) was determined three times on BHK-21 cells. Error bars indicate standard deviations.
Vet. Res. (2010) 41:30 W. Cong et al.
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virus infection in guinea pigs
The data obtained in the cell culture and
suckling mice assays demonstrated that siRNA
targetedtoconservedregionsoftheFMDVgen-
omecouldbeeffectiveagainstFMDVineithera
speciﬁc or a cross-inhibitory manner. The poten-
tial of RNAi as an antiviral strategy against
FMDV in relevant animal systems is of great
interest. The fact that attenuated Salmonella is
widely used as a DNA vaccine vector made us
choose it as the vector for siRNA delivery. To
test the anti-FMDV potentialof rS.cho,w ech al -
lenged guinea pigs pretreated by intramuscular
injection of rS. cho constructs with FMDV
HKN/2002. All saline-treated animals devel-
opedthemajorclinicalsignofFMD,theappear-
ance of vesicles on the feet, within 48 h of
challenge (Tab. I). Guinea pigs treated with
pLacZ/S. cho were not protected at all, though
the clinical signs were delayed in some animals,
asshowninTable I.However,4of5guineapigs
pretreated with 10
9 CFU of p3D-NT56/S. cho
and challenged with 50 ID50 of HKN/2002
developed none of the clinical signs such as
vesicles or high fever. These results indicated
that S. cho-delivered siRNA exerted in vivo
inhibitory activity against FMDVin guineapigs.
We further evaluated the potential of treat-
ments with an FMDV-speciﬁc rS. cho and
rAd5 mixture in guinea pigs. Three of the ﬁve
animals in the group treated with the p3D-
NT56/S. cho+Ad5-POL mixture were com-
pletely protected as determined by the absence
of vesicles on their feet (Tab. I). No signiﬁcant
increase in antiviral effect was achieved in this
group when compared to the group treated with
p3D-NT56/S. cho alone (Tab. I). This indicated
that a simple combination of two vectors could
not improve the protection of animals.
3.4. Treatment with p3D-NT56/S. cho confers
signiﬁcant resistance against FMDV
infection in swine
Based on the experiments in guinea pigs, we
evaluated the antiviral activity of p3D-NT56/S.
cho in swine. Animals were intramuscularly
inoculated with 5 · 10
9 CFU of p3D-NT56/S.
cho and challenged 24 h later with 100 ID50
of HKN/2002. All of the saline-treated swine
developed acute signs of FMD, including vesi-
cles and fever (Fig. 3A). Animal 1-48 had ves-
icles as early as 3 dpc, and its symptoms were
extraordinarily severe. In comparison with this
group, animals inoculated with either pLacZ/
S. cho or S. cho showed no signs of signiﬁcant
antiviral activity (Figs. 3B and 3C). However,
p3D-NT56/S. cho conferred marked antiviral
activity that could be seen for more than 9 days
of observation (Fig. 3D). Animal 2-7 in this
group developed a fever but no vesicles during
the observation period. Although animals 5-6,
Figure 2. siRNA synthesized in vivo induce antiviral response in suckling mice and promote survival
after FMDV infection. Suckling mice were challenged by subcutaneous injection in the neck with 20 LD50
of HKN/2002 (A) or 20 LD50 of YNBS/58 (B) after 6 h of treatment with either control plasmids or FMDV-
speciﬁc siRNA-expressing plasmids. All animals were observed for 6 days after challenge.
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fewer and developed much later. In another
group inoculated with 5 · 10
10 CFU of p3D-
NT56/S. cho, none of the animals were pro-
tected (Fig. 3E), but animal 7-1 showed delayed
disease onset and milder disease than the con-
trol animals.
Serum samples were collected at 0, 7, and
14 dpcandtestedforthepresenceofneutralizing
antibodies and antibodies against viral NS pro-
tein 3ABC of FMDV. No animals had marked
FMDV-speciﬁc antibodies at 0 dpc, including
anti-3ABC antibodies (Tab. II). Animals in the
control groups treated with saline, S. cho or
pLacZ/S.chodevelopedahighneutralizinganti-
body response at 7 and 14 dpc, suggesting that
these animals were exposed to a very large
amount of FMDV (Tab. II). Avery low neutral-
izing antibodyresponse was detectedat7 dpc in
animals (2-7, 5-6, 3-3, 1-1, 7-1 and 1-34) that
wereinoculatedwithp3D-NT56/S.cho,suggest-
ing that these animals effectively suppressed
virus replication. A key distinguishing feature
ofinfectedanimalsisthe inductionofantibodies
against the polyprotein 3ABC of FMDV [45].
Using an LPB-ELISA, we showed that the
animals developing FMD had signiﬁcantly
higher levels of antibodies against 3ABC as
compared to the disease-free animals (Tab. II).
Theseresultsofserologicalanalysiswereconsis-
tent with the observation of clinical signs.
4. DISCUSSION
Strategies aimed at conferring rapid and efﬁ-
cient protection against FMDV have to face one
main challenging factor: the rapid, acute infec-
tion caused by this virus, which makes the
absence of sufﬁcient amounts of antibodies or
other interfering factors essential for protection.
The traditional emergency vaccines based on
virus inactivation could be effective in prevent-
ing disease within 4 to 5 days post-vaccination,
due to a critical role for innate immune defenses
[2, 39]. However, signs of disease can appear as
early as 2 days post-exposure. Thus, it is neces-
sary to develop antiviral strategies capable of
inducing early protection in the face of an out-
break that threatens to spread widely. Recently,
we and several other groups demonstrated that
RNAi can be potentially used as a therapeutic
Table I. Treatment with FMDV-speciﬁc rS. cho or a mixture of rS. cho and rAd5 inhibits FMDV HKN/2002
infection in guinea pigs
a.
Group Treatment
(CFU or PFU)
b
No. protected/no. challenged for dpc p
c
12345 6 1 4
Saline 3/5 0/5 – – – – – AC
pLacZ/S. cho 10
9 4/5 1/5 0/5 – – – – 0.308
p3D-NT56/S. cho 10
9 5/5 5/5 4/5 – – – – 0.00313
p3D-NT19/S. cho 10
9 5/5 2/5 – – – – – 0.0571
S. cho 10
9 1/5 1/5 0/5 – – – – 0.787
pLacZ/S. cho 10
8 4/5 0/5 – – – – – 0.513
p3D-NT56/S. cho 10
8 5/5 3/5 2/5 2/5 1/5 – – 0.029
pLacZ/S. cho 10
10 5/5 1/5 1/5 0/5 – – – 0.0951
p3D-NT56/S. cho 10
10 5/5 4/5 2/5 2/5 1/5 – – 0.0116
Ad5-LacZ+pLacZ/S. cho 10
6 +1 0
9 2/5 0/5 – – – – – 0.549
Ad5-POL+p3D-NT56/S. cho 10
6 +1 0
9 5/5 3/5 – – – – – 0.029
Ad5-LacZ 10
6 3/5 1/5 1/5 0/5 – – – 0.602
Ad5-POL 10
6 5/5 5/5 3/5 2/5 – – – 0.00313
a –: Score is the same as the day before.
b CFU for rS. cho and PFU for rAd5.
c Statistical analysis by the log rank test.
Days post-challenge (dpc) and AC: as controls.
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[6, 24, 33]. However, to be effective against
RNA viruses such as FMDV, which are highly
antigenically variable, the siRNA must be tar-
geted to conserved regions. Here, we provide
evidence that siRNA targeted to conserved
regions of the FMDV genome could effectively
inhibit the virus replication of multiple FMDV
serotypes.
In this study, three genes, namely 3D, VP4
and 2B, were selected as targets for three rea-
sons. First, it is well known that different siR-
NA have different efﬁciencies in inducing
RNAi [21–23]. Second, the proteins encoded
by these genes have essential functions in dif-
ferent phases of the viral replication cycle.
The RNA-dependent RNA polymerase (3D) is
a key enzyme in viral RNA replication
[34, 44]; VP4 is a structural protein, located
inside the mature virus particle, and is involved
in conversion of provirions to mature virions
[1]; and 2B is involved in membrane rearrange-
ments required for viral RNA replication and
capsid assembly [19]. Third, we compared
14 reported FMDV isolates of serotype O and
serotype Asia I. The analysis showed that the
sequences in these regions are relatively con-
served between different FMDV serotypes.
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Figure 3. Antiviral activity of rS. cho in swine. Animals were treated with saline (A), S. cho (B), pLacZ/
S. cho (C), p3D-NT56/S. cho (D), or a high dose of p3D-NT56/S. cho (E) and challenged as described in the
Materials and Methods section. After challenge, lesion scores were assigned to the animals according to the
number of digits plus mouth with vesicles.
Salmonella-mediated RNAi against FMDV Vet. Res. (2010) 41:30
(page number not for citation purpose) Page 9 of 13Previously, De los Santos et al. [11] found
that an siRNA directed against a conserved
sequence within the coding region of viral NS
protein 2B of FMDV was capable of inhibiting
virus replication in infected porcine cells by
approximately 97–98%. And this 2B-speciﬁc
siRNA reduced virus yield in cells infected with
4 different FMDV serotypes. Liu et al. [28]
demonstrated that siRNA directed to the con-
served regions of the FMDV genome, namely
VP4 and 3D, could inhibit the replication of
both FMDV strains, serotype O and Asia I.
Our study indicates that p3D-NT56 and p2B-
NT25 dramatically inhibited viral replication
in cultured cells that were susceptible to FMDV
of either serotype O or serotype Asia I. Suck-
ling mice treated with the siRNA-expressing
plasmids had signiﬁcantly reduced susceptibil-
ity to both serotype O and serotype Asia I of
FMDV.
Efﬁcient delivery of siRNA into cells or
organs in vivo remains a major bottleneck in
antiviral therapy. A number of methods for
delivering siRNA in vivo have been tested
[3, 15, 27, 49]. Liposome formulations are gen-
erally used [3, 15, 49], but a simple intranasal
administration of naked siRNA has been shown
to be effective against respiratory viruses [3].
Chen et al. [6] used adenoviruses as the vectors
for the delivery of duplex RNA to the target
tissue, and total RNA were extracted from ﬁve
tissues (oropharynx, lung, liver, muscle, and
epidermis of the foot) of guinea pigs treated
with rAd5 and assayed for rAd5 GFP mRNA.
The vast majority of rAd5 was found in the
liver. In cloven-hoofed animals, the oropharynx
has been identiﬁed as the major site of FMDV
replication during acute and persistent infection
[37]. Brown et al. [4] indicated that the FMDV
RNA was localized in the tonsil, pharynx and
Table II. Serological analysis of sera from swine inoculated with rS. cho.
Group Animal no. Neutralizing antibody
a Mean % inhibition of antibody against
3ABC
b ±S D
Day 0 Day 7 Day 14 Day 0 Day 7 Day 14
Saline 28-8   3 108 362 ND
c ND ND
1-48   3 362 362 ND ND ND
3-2   3 128 362 2.6 ± 0.2 39.5 ± 0.1 36.2 ± 2.0
S. cho 6-4   3 362 362 12.9 ± 2.9 42.9 ± 1.1 55.9 ± 1.1
4-6   3 180 362 13.6 ± 1.9 54.5 ± 1.9 63.2 ± 0.7
pLacZ/S. cho 6-2   3 180 362 ND ND ND
43-14   3 180 362 ND ND ND
43-5   3 256 256 ND ND ND
49-3   3 128 180 ND ND ND
p3D-NT56/S. cho 2-7   3 23 180 12.16 ± 1.1 12.6 ± 2.4 25.8 ± 0.4
5-6   3 12 180 6.5 ± 1.0 10.1 ± 0.3 27.8 ± 4.2
3-3   3 12 180 12.8 ± 0.8 9.5 ± 0.2 32.9 ± 5.2
1-1   3 23 180 11.9 ± 0.5 21.2 ± 3.8 29.5 ± 2.7
p3D-NT56/S. cho
d 1-3   3 108 128 3.1 ± 1.0 36.5 ± 1.2 50.0 ± 4.3
7-1   3 23 180 6.4 ± 0.0 27.9 ± 0.2 33.6 ± 3.2
3-4   3 108 180 7.4 ± 0.7 39.1 ± 1.8 45.5 ± 0.2
1-34   3 64 180 ND ND ND
a Highest dilution that resulted in a 50% reduction in the number of HKN/2002 plaques.
b Mean percent inhibition of the optical density as determined by ELISA.
c ND: not determined.
d Inoculation with a high dose of rS. cho.
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tissue distribution of rAd5 and FMDV is prob-
ably related to antiviral activity of rAd5 in vivo.
Our overall goal was to ﬁnd a siRNA vector
that can spread through the similar infection
and transmission tract as FMDV. Attenuated
Salmonella has become popular for expressing
foreign antigens as a vaccine strain or as a
delivery vector of DNAvaccines [10, 12]. Gray
et al. [18]f o u n dt h a tS. choleraesuis was most
often recovered from the lymph node, tonsil,
lung and alimentary tract of swine inoculated
with S. choleraesuis. These studies aroused
our interest in evaluating the potential of Sal-
monella as a vector for siRNA delivery. We
found that 80% of guinea pigs were completely
protected when inoculated with 10
9 CFU of
p3D-NT56/rS. cho, and that rS. cho also con-
ferred marked antiviral activity in swine. Sur-
prisingly, the antiviral potential of RNAi was
e v i d e n t l yi m p a i r e di na n i m a l st r e a t e dw i t ha
high dose of rS. cho. Srinivasan et al. [43] dem-
onstrated that variation in the initial dose of
infection with Salmonella had a profound effect
on the response of Salmonella ﬂagellin-speciﬁc
CD4 Tcells in vivo, and that low-dose infection
could evade Salmonella ﬂagellin-speciﬁc T cell
activation completely. Mercado et al. [32]
reported that a 25-fold dilution in bacterial chal-
lenge dose did not signiﬁcantly alter the size or
kinetics of the Listeria LLO91–99-speciﬁc CD8
Tcell response. The low-dose effect may repre-
sent a general mechanism to increase virulence.
The immune evasion could probably make the
lower dose salmonella more efﬁcient as a vector
to carry siRNA.
Because Ad5 lacking E1A and E1B had
been used for delivery of RNAi by several
groups [6, 40, 48], we evaluated the antivi-
ral potential of combination inoculations of
rS. cho and rAd5 in guinea pigs. The results
indicate that no signiﬁcant increase in antiviral
effect was achieved in the group treated
with the p3D-NT56/S. cho+Ad5-POL mix-
ture, as compared to the group treated with
p3D-NT56/S. cho alone. Kim et al. [25]
attempted to improve the antiviral effect by
use of a mixture of two adenovirus constructs,
by giving two injections of shRNA prior to
FMDV challenge and by giving injections
after FMDV challenge. The high survival rate
was maintained by treatment with adenovi-
ruses post-challenge. These results could
encourage us to seek more efﬁcient methods
of treatment.
In conclusion, a licensed strain of S. chole-
raesuis has a potential as an RNAi delivery sys-
tem. This strain is very safe for swine, relatively
inexpensive to manufacture and well suited for
large-scale administration. However, it remains
unclear the attenuated Salmonella how to deli-
ver siRNA in vivo. Future studies relevant to
cytokine and distribution of siRNA are neces-
sary to examine this issue in more detail.
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